Cholinergic Treatment Strategies in Alzheimer's Disease

Alzheimer’s disease is characterised by progressive cognitive decline closely linked to loss of cholinergic neurons and reduced levels of the neurotransmitter acetylcholine in cortical and hippocampal circuits. Classical therapeutic approaches centre on acetylcholinesterase inhibitors, which prolong synaptic acetylcholine availability to mitigate symptoms of memory impairment and executive dysfunction. Beyond these, recent strategies include allosteric modulation of muscarinic receptors, targeted drug-delivery systems to enhance central nervous system exposure, and combination regimens pairing cholinergic agents with glutamatergic modulators to address multifactorial pathology. Advances also encompass novel routes of administration that bypass the blood–brain barrier, as well as molecular designs that confer dual activity against cholinesterase and additional neurodegenerative targets. Collectively, these interventions aim to restore cholinergic tone, bolster synaptic plasticity, and slow clinical progression, while improving tolerability and compliance in a global ageing population.

Research from Nature Portfolio

Recent studies have demonstrated that selective optogenetic activation of basal forebrain cholinergic neurons in transgenic Alzheimer’s models restores synaptic plasticity and long-term spatial memory, highlighting the therapeutic potential of cell-type-specific neuromodulation.

In parallel, discovery of novel positive allosteric modulators of the muscarinic M1 receptor has shown enhanced hippocampal cholinergic signalling, reduced amyloid-induced synaptic deficits and improved performance in learning paradigms, offering a receptor-targeted approach to augment endogenous acetylcholine.

Cholinergic Treatment Strategies in Alzheimer's Disease publication trend

The graph below shows the total number of articles in cholinergic treatment strategies in alzheimer's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Acetylcholinesterase inhibitor: A compound that blocks the enzyme degrading acetylcholine, prolonging neurotransmitter action.

Positive allosteric modulator: A molecule that binds to a receptor’s non-active site to enhance its response to the natural ligand.

Intracalvariosseous administration: Direct delivery of therapeutic agents into the diploic space of the skull to access the brain.

Microspheres: Biodegradable polymer particles engineered for controlled, sustained release of encapsulated drugs.

Basal forebrain cholinergic system: Neuronal network providing cortical and hippocampal cholinergic innervation critical for cognition.

References

1. Intracalvariosseous administration of donepezil microspheres protects against cognitive impairment by virtue of long-lasting brain exposure in mice. Theranostics (2024).
2. Pro-cognitive effects of dual tacrine derivatives acting as cholinesterase inhibitors and NMDA receptor antagonists. Biomedicine & Pharmacotherapy (2024).
3. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review. International Journal of Clinical Practice (2009).